Q/C Technologies, Inc. (NASDAQ:QCLS) — Market Cap & Net Worth
Market Cap & Net Worth: Q/C Technologies, Inc. (QCLS)
Q/C Technologies, Inc. (NASDAQ:QCLS) has a market capitalization of $21.60 Million ($21.60 Million) as of August 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24808 globally and #5222 in its home market, demonstrating a -14.86% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Q/C Technologies, Inc.'s stock price $2.75 by its total outstanding shares 7853429 (7.85 Million). Review Q/C Technologies, Inc. (QCLS) total liabilities to assess the company's total debt and financial obligations.
Q/C Technologies, Inc. Market Cap History: 2025 to 2026
Q/C Technologies, Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $31.34 Million to $21.60 Million (0.00% CAGR).
Q/C Technologies, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Q/C Technologies, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of QCLS by Market Capitalization
Companies near Q/C Technologies, Inc. in the global market cap rankings as of August 4, 2026.
Key companies related to Q/C Technologies, Inc. by market ranking:
- Seagate Technology PLC (NASDAQ:STX): Ranked #112 globally with a market cap of $186.35 Billion USD.
- Western Digital Corporation (NASDAQ:WDC): Ranked #117 globally with a market cap of $181.72 Billion USD.
- Arista Networks (NYSE:ANET): Ranked #131 globally with a market cap of $171.79 Billion USD.
- Sandisk Corp (NASDAQ:SNDK): Ranked #279 globally with a market cap of $92.46 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #112 | Seagate Technology PLC | NASDAQ:STX | $186.35 Billion | $831.06 |
| #117 | Western Digital Corporation | NASDAQ:WDC | $181.72 Billion | $527.22 |
| #131 | Arista Networks | NYSE:ANET | $171.79 Billion | $184.89 |
| #279 | Sandisk Corp | NASDAQ:SNDK | $92.46 Billion | $1288.03 |
Q/C Technologies, Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, Q/C Technologies, Inc.'s market cap moved from $31.34 Million to $ 21.60 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $21.60 Million | -31.08% |
| 2025 | $31.34 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Q/C Technologies, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $21.60 Million USD |
| MoneyControl | $21.60 Million USD |
| MarketWatch | $21.60 Million USD |
| marketcap.company | $21.60 Million USD |
| Reuters | $21.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Q/C Technologies, Inc.
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, … Read more